Movement Alert｜AKESO Rises 3.04% in Regular Trading, Third Indication of Bispecific Antibody Ivonescimab Approved by NMPA

Market Focus

Aug 13

On August 13, AKESO rose 3.04% in regular trading, trading at 104.7 HKD/share, with turnover of approximately HKD 103 million.

On the news front, AKESO announced on August 12 that its self-developed PD-1/VEGF bispecific antibody Ivonescimab (marketed as Yidafang) in combination with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (SQ-NSCLC) has been approved by China's National Medical Products Administration. This marks the third approved indication for Ivonescimab.

The approval was based on positive results from the Phase III randomized, controlled, multi-center clinical study HARMONi-6/AK112-306, which compared Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in first-line treatment of advanced SQ-NSCLC. Additionally, the company recently completed first patient dosing in a Phase II study of its novel Trop2/Nectin-4 bispecific ADC combined with Ivonescimab for breast cancer, further advancing its IO2.0+ADC2.0 strategy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1183521922"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183521922\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183521922?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183521922","market":"hk","top_or_hot":-1,"title":"Movement Alert｜AKESO Rises 3.04% in Regular Trading, Third Indication of Bispecific Antibody Ivonescimab Approved by NMPA","media":"Market Focus","content":"<p><p>On August 13, AKESO rose 3.04% in regular trading, trading at 104.7 HKD/share, with turnover of approximately HKD 103 million.</p><p>On the news front, AKESO announced on August 12 that its self-developed PD-1/VEGF bispecific antibody Ivonescimab (marketed as Yidafang) in combination with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (SQ-NSCLC) has been approved by China's National Medical Products Administration. This marks the third approved indication for Ivonescimab.</p><p>The approval was based on positive results from the Phase III randomized, controlled, multi-center clinical study HARMONi-6/AK112-306, which compared Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in first-line treatment of advanced SQ-NSCLC. Additionally, the company recently completed first patient dosing in a Phase II study of its novel Trop2/Nectin-4 bispecific ADC combined with Ivonescimab for breast cancer, further advancing its IO2.0+ADC2.0 strategy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AKESO Rises 3.04% in Regular Trading, Third Indication of Bispecific Antibody Ivonescimab Approved by NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AKESO Rises 3.04% in Regular Trading, Third Indication of Bispecific Antibody Ivonescimab Approved by NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-13 09:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 13, AKESO rose 3.04% in regular trading, trading at 104.7 HKD/share, with turnover of approximately HKD 103 million.</p><p>On the news front, AKESO announced on August 12 that its self-developed PD-1/VEGF bispecific antibody Ivonescimab (marketed as Yidafang) in combination with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (SQ-NSCLC) has been approved by China's National Medical Products Administration. This marks the third approved indication for Ivonescimab.</p><p>The approval was based on positive results from the Phase III randomized, controlled, multi-center clinical study HARMONi-6/AK112-306, which compared Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in first-line treatment of advanced SQ-NSCLC. Additionally, the company recently completed first patient dosing in a Phase II study of its novel Trop2/Nectin-4 bispecific ADC combined with Ivonescimab for breast cancer, further advancing its IO2.0+ADC2.0 strategy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1183521922","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183521922","pubTimestamp":1786585192,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 13, AKESO rose 3.04% in regular trading, trading at 104.7 HKD/share, with turnover of approximately HKD 103 million.On the news front, AKESO announced on August 12 that its self-developed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"异动提醒|AKESO常规交易大涨3.04%，双特异性抗体Ivonescimab第三个适应症获NMPA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On August 13, AKESO rose 3.04% in regular trading, trading at 104.7 HKD/share, with turnover of approximately HKD 103 million.On the news front, AKESO announced on August 12 that its self-developed PD-1/VEGF bispecific antibody Ivonescimab (marketed as Yidafang) in combination with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (SQ-NSCLC) has been approved by China's National Medical Products Administration. This marks the third approved indication for Ivonescimab.The approval was based on positive results from the Phase III randomized, controlled, multi-center clinical study HARMONi-6/AK112-306, which compared Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in first-line treatment of advanced SQ-NSCLC. Additionally, the company recently completed first patient dosing in a Phase II study of its novel Trop2/Nectin-4 bispecific ADC combined with Ivonescimab for breast cancer, further advancing its IO2.0+ADC2.0 strategy.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}